title: The future of autologous stem cell transplantation in myeloma.
abstract: Autologous stem cell transplantation (ASCT) has long been considered frontline therapy for newly diagnosed myeloma patients. This Spotlight examines the role of ASCT in the era of novel drugs and argues that ASCT should continue to be considered for eligible patients. A combination of novel drugs with ASCT in a sequential treatment approach can attain long-term survival and perhaps cure a subset of patients. ASCT will likely remain an important platform to develop curative strategies in the foreseeable future.
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and.
authors.forename: Frits
authors.identifier: http://orcid.org/0000-0001-9959-1282
authors.initials: F
authors.lastname: van Rhee
authors.affiliation: Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and.
authors.forename: Bart
authors.initials: B
authors.lastname: Barlogie
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D018365:Neoplasm, Residual; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000639:trends*; D014182:Transplantation, Autologous; D016896:Treatment Outcome